# Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

> **NCT05482074** · PHASE2 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Recurrent Metastatic Melanoma
- Cutaneous Melanoma
- Mucosal Melanoma
- Uveal Melanoma

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05482074
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-04
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Principal Investigator left the institute
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482074, "Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05482074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*